cancer biosimilars

Views & Analysis

Adrian van den Hoven of Medicines for Europe addresses three big questions facing the biosmilars sector in Europe in 2018.

News

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.